CreatorsPublishersAdvertisers
View more in
Cancer

Adaptimmune Q&A: an alternative approach to T-cell cancer therapies

pharmaceutical-technology.com
 30 days ago

Cover picture for the articleUK-headquartered biopharmaceutical company Adaptimmune is on a mission to transform cancer immunotherapy by engineering T-cells to target and destroy cancer, including solid tumours. While chimeric antigen receptor (CAR) T-cell therapies have shown great success in treating certain cancers, they have so far proven less effective at tackling solid tumours – a gap that Adaptimmune hopes to fill with its T-cell receptor technology.

www.pharmaceutical-technology.com

Comments / 0

Comments / 0